From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approval

A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk.

In this case study, learn how we partnered with our client to reestablish FDA engagement, resolve the clinical hold within 30 days, and successfully navigate the path to BLA approval and priority review.

A Proven Path from Setback to Approval

CMC changes can introduce significant regulatory risk, especially during late-stage development. Without clear alignment from the FDA, even well-intended changes can delay timelines and jeopardize commercialization plans.

This case study demonstrates how a strategic, communication-driven approach can not only resolve immediate challenges, but also position your program for long-term success. From lifting a clinical hold to achieving priority review and approval, this example highlights the value of experienced regulatory guidance at every stage.

What You’ll Learn

• How to effectively respond to FDA concerns following a major CMC change
• Strategies for reestablishing productive communication with the FDA
• Key considerations for designing comparability and bridging programs
• Best practices for preparing high-quality briefing packages and regulatory interactions
• How to maintain momentum through BLA submission, review, and inspection readiness

Learn how our client successfully overcame a critical regulatory hurdle and achieved approval, while strengthening its relationship with the FDA and preparing for commercialization.